Table 5.
Clinically significant cut offs in individual PBC domains and total PBC score based on mean ± 2SD for the control values
| Symptoms domain | Control subject value | Clinical cut off | Positive in PBC population (n = 374%) | , | Positive in Larissa PBC population (n = 300, %) | Positive in Crete PBC population (n = 74, %) | |
|---|---|---|---|---|---|---|---|
| Symptoms | 7.45 ± 2.19 | ≥ 12 | 179 (48.0) | 138 (46.0) | 45 (61.0) | ||
| Fatigue | 11.78 ± 1.49 | ≥ 15 | 292 (78.1) | 231 (77.0) | 61 (82.4) | ||
| Cognition | 7.06 ± 2.10 | ≥ 12 | 121 (32.4) | 81 (27.0) | 40 (54.0) | ||
| Emotional | 1.02 ± 0.26 | ≥ 2 | 374 (100.0) | 300 (100.0) | 74 (100.0) | ||
| Social | 8.96 ± 1.95 | ≥ 13 | 301 (80.5) | 238 (79.3) | 63 (85.1) | ||
| PBC-40 scale | 36.37 ± 6.64 | ≥ 50 | 327 (87.4) | 260 (87.0) | 67 (91.0) |
Data presented as n (%) of PBC patients with clinically significant symptoms in PBC (total PBC population and individual PBC cohorts). PBC: primary biliary cholangitis.